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Background: Molecular imaging of breast cancer is a promising emerging technology, potentially able to improve
clinical care. Valid imaging targets for molecular imaging tracer development are membrane-bound hypoxia-related
proteins, expressed when tumor growth outpaces neo-angiogenesis. We performed a systematic literature review
and meta-analysis of such hypoxia marker expression rates in human breast cancer to evaluate their potential as
clinically relevant molecular imaging targets.
Methods: We searched MEDLINE and EMBASE for articles describing membrane-bound proteins that are related to
hypoxia inducible factor 1α (HIF-1α), the key regulator of the hypoxia response. We extracted expression rates of
carbonic anhydrase-IX (CAIX), glucose transporter-1 (GLUT1), C-X-C chemokine receptor type-4 (CXCR4), or insulin-like
growth factor-1 receptor (IGF1R) in human breast disease, evaluated by immunohistochemistry. We pooled study
results using random-effects models and applied meta-regression to identify associations with clinicopathological
variables.
Results: Of 1,705 identified articles, 117 matched our selection criteria, totaling 30,216 immunohistochemistry results.
We found substantial between-study variability in expression rates. Invasive cancer showed pooled expression rates
of 35% for CAIX (95% confidence interval (CI): 26-46%), 51% for GLUT1 (CI: 40-61%), 46% for CXCR4 (CI: 33-59%), and
46% for IGF1R (CI: 35-70%). Expression rates increased with tumor grade for GLUT1, CAIX, and CXCR4 (all p < 0.001),
but decreased for IGF1R (p < 0.001). GLUT1 showed the highest expression rate in grade III cancers with 58% (45-69%).
CXCR4 showed the highest expression rate in small T1 tumors with 48% (CI: 28-69%), but associations with size were
only significant for CAIX (p < 0.001; positive association) and IGF1R (p = 0.047; negative association). Although based
on few studies, CAIX, GLUT1, and CXCR4 showed profound lower expression rates in normal breast tissue and benign
breast disease (p < 0.001), and high rates in carcinoma in situ. Invasive lobular carcinoma consistently showed lower
expression rates (p < 0.001).
Conclusions: Our results support the potential of hypoxia-related markers as breast cancer molecular imaging targets.
Although specificity is promising, combining targets would be necessary for optimal sensitivity. These data could help
guide the choice of imaging targets for tracer development depending on the envisioned clinical application.
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In the past decades, conventional breast imaging modal-
ities such as (digital) mammography, breast ultrasound,
and more recently dynamic contrast enhanced magnetic
resonance imaging (DCE-MRI), have improved detection,
characterization, and management of breast cancer.
Although these imaging modalities are valuable in clinical
practice, novel imaging strategies such as molecular
imaging promise additional advantages. With molecular
imaging techniques, breast cancer could be detected even
before anatomical changes occur that are required for
visualization with currently used imaging modalities,
making it valuable for early detection or screening. For
diagnostic purposes, more informative characterization of
breast cancer could result in less unnecessary biopsies.
Furthermore, improved imaging of the extent of disease
could lead to better preoperative planning and to per-
operative guidance, increasing the primary surgery success
rate. Molecular imaging could also be applied to demon-
strate the presence of appropriate molecular targets in the
primary tumor, lymph node and distant metastasis (in vivo
receptor status determination), and could therefore be
useful to tailor therapy to individual patients and to
monitor therapy response [1-6]. Molecular imaging of
tumor metabolism using 18F-fluorodeoxyglucose (18F-FDG)
Positron Emission Tomography is currently common for
imaging and staging of advanced breast cancer. However, it
is of limited value in evaluation of early breast cancer be-
cause of limited spatial resolution, non-visibility of tumors
with low 18F-FDG avidity, and low specificity [7].
Imaging of tumor hypoxia could be a feasible alterna-
tive strategy for molecular imaging of breast cancer.
Hypoxia is a frequent phenomenon in solid tumors that
arises due to limited perfusion [8,9], and might therefore
be more specific than 18F-FDG imaging. Direct imaging
of tumor hypoxia using oxygen mimetics (e.g. with radi-
olabelled 2-nitroimidazole derivatives (18F-FMISO, 18F-
FAZA, 18F-EF5) and other molecules such as Cu-ATSM)
has been investigated in several clinical studies [10].
However, the biodistribution properties of these mole-
cules result in images with low contrast.
Molecular imaging using (monoclonal) antibodies or
antibody fragments (e.g. single chain variable fragments
(scFv), antibody-binding fragments (Fab), variable domains
of the heavy chain of heavy chain-only antibodies (VHH)
or affibodies) that have high affinity for markers that are
expressed in breast cancer under hypoxic conditions could
improve imaging contrast [11-13]. The molecules that are
targeted with these antibodies or fragments should ideally
be highly prevalent in (breast) cancer, and expression
should preferably be already present at the initial stage of
tumorigenesis. Expression of these molecules should be
absent or low in non-affected tissue and benign breast dis-
ease for high specificity, although the relative importanceof these properties depends on the envisioned clinical
application. For screening purposes, specificity of the
target of interest should be high and for application in a
diagnostic setting, expression prevalence of the target in
breast cancer should be sufficient. For intra-operative
guidance, high expression prevalences are less important
as pre-operative target selection is possible based on a
diagnostic (core) biopsy. However, distribution of the target
within the tumor should be homogenous when used for
assessment of tumor margins. Furthermore, extracellular
membrane bound molecules are most attractive, as these
are more easily accessible for most antibodies or antibody
fragments compared to intracellular molecules [14].
Hypoxic conditions result in focal expression of hypoxia
inducible factor 1α (HIF-1α), the key regulator of the
hypoxia response [8,15,16]. The downstream targets of
HIF-1α, carbonic anhydrase IX (CAIX), glucose transporter
1 (GLUT1) and C-X-C chemokine receptor type 4
(CXCR4) [17-20], and insulin-like growth factor 1 receptor
(IGF1R) that maintains the hypoxia response via HIF-1α
stabilization [21-23], are expressed on the plasma mem-
brane of breast cancer cells and are therefore potentially
suitable candidates for molecular imaging of hypoxic
tumors with antibodies or antibody fragments.
Despite the apparent potential of these hypoxia related
proteins, expression patterns in human breast cancer,
normal breast tissue and benign breast diseases, as well
as expression in tumor margins and heterogeneity within
tumors are not well established. To evaluate whether
molecular imaging using these targets could be clinically
relevant, we performed a systematic literature review
and meta-analysis to quantify expression prevalences of
these hypoxia markers in breast disease as assessed by
immunohistochemistry (IHC), investigated relations
with clinicopathological characteristics, and assessed the
influence of specimen handling on these prevalences.
These data could help guide the choice of relevant
imaging targets for future tracer development towards
clinical studies.Methods
Literature search
We performed a systematic search in the databases of
MEDLINE and EMBASE on August 21st, 2012. Search
terms included synonyms for the targets of interest
(CXCR4, GLUT1, CAIX, and IGF1R), combined with
‘breast’ and ‘mamm*’. The full search syntax can be
found in Table 1. We applied no restrictions on publica-
tion date. The search in the database of EMBASE was
limited to articles that were not indexed with a
MEDLINE ID, and conference abstracts were excluded.
Duplicate articles were manually removed from the
search results.
Table 1 Search strategy used to identify publications of interest regarding prevalence of hypoxia proteins in benign
and malignant breast tissue
Target Synonyms used
CAIX CAIX OR CA-IX OR “CA IX” OR CA9 OR CA-9 OR “CA 9” OR “carbonic anhydrase IX” OR “carbonic anhydrase 9”
GLUT1 GLUT1 OR GLUT-1 OR “glucose transporter 1”
CXCR4 CXCR4 OR CXCR-4 OR CXC-R4 OR “CXC chemokine receptor-4”
IGF1R “insulin like growth factor 1 receptor” OR “insulin like growth factor I receptor” OR IGF1R OR IGF-1R OR IGFR OR IGF-IR OR IGF1-R
Search terms were combined with ‘breast’ and ‘mamm*’. For MEDLINE, ‘[tiab]’ was added to each search term, and for EMBASE, ‘ti;ab;’ was added to each
search term.
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Article eligibility was assessed by three reviewers (AA,
AvB, JV) through independent screening of all titles and
abstracts from the search result (triple read). We ex-
cluded articles based on predefined criteria, disagree-
ments were resolved by discussion. An overview of the
selection procedure is shown in Figure 1. Reasons for
exclusion of articles based on title or abstract were: (1)Potentially relevant articles identified through MEDLINE 
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Figure 2 (See legend on next page.)
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Figure 2 Expression prevalence of CAIX. A Systematic literature review of CAIX prevalence in breast cancer assessed by immunohistochemistry,
according to reported staining threshold. Legend: Dashed gray reference line: overall random-effects prevalence estimate. Abbreviations: Staining
threshold: weak intensity (WI), moderate intensity (MI), strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not
stated (NS). B Systematic literature review of CAIX prevalence in normal breast tissue, benign breast diseases and carcinoma in situ assessed by
immunohistochemistry. Legend: Dashed line represents random effect summary prevalence estimate for invasive cancer within studies reporting
also on normal, benign and/or precancerous breast tissue (4 studies). Abbreviations: Staining threshold: weak intensity (WI), moderate intensity (MI),
strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not stated (NS).
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(e.g. quantitative Polymerase Chain Reaction or Western
Blot, N = 64), (3) all or a non-definable part of patients
received neo-adjuvant therapy (which could profoundly
alter biomarker status, N = 10), or (4) the prevalence of the
target of interest was not reported and could not be derived
from the published data (N = 20). All references of the
remaining articles were reviewed to retrieve articles initially
missed in the search syntax.Data extraction and statistical analysis
We extracted relevant information of each study (e.g.
study and population characteristics, patient and tumor
characteristics, and IHC methodology). Then, for each
study and per target of interest, we annotated the number
of lesions stated as target-positive and the total number
of lesions, either directly or through recalculation based
on the information stated in the article. Lesions of interest
were invasive breast cancers, carcinoma in situ, benign
breast lesions, or normal breast tissue. For invasive
cancers, we grouped studies describing similar cut-off
levels for marker positivity. When a study described
multiple cut-off levels, the level corresponding to the
most used cut-off among other included studies was used,
as established after collecting all data. If patient data was
used in more than one article (i.e. when articles referred
to the same study, or assessed a comparable number of
patients from the same hospital in a similar inclusion
period to evaluate the expression of the same hypoxia
marker), then only the article with the largest number of
patients was included in the review and meta-analysis. A
subgroup was defined for studies investigating membran-
ous staining patterns only. Also, in order to assess applic-
ability of the targets for human molecular imaging
studies, we identified articles using a stringent or high
cut-off value and preferentially membranous staining
localization, as these studies provide the best evidence
for high expression levels of the target. Furthermore,
subgroups were defined according to tumor size (based
on the TNM staging system), histological grade, histo-
logical subtype, and specimen handling method (i.e. if full
tissue sections or tissue microarrays (TMA) were investi-
gated), when stated. To assess specificity of the investigated
markers, studies were grouped according to tissue typesother than invasive breast cancer (normal tissue, benign
breast disease, carcinoma in situ).
Then, we pooled prevalence rates across studies using
a random-effects model, allowing for between-study
heterogeneity. We fitted a linear mixed model using the
exact binomial approach with the restricted maximum
likelihood method [24]. We tested for subgroup differ-
ences using meta-regression analysis with subgroup
indicators as fixed effects and the individual studies as
random effects in the models. Besides the pooled
prevalence estimates, we report predictive intervals as
suggested by Higgins et al. for the evaluation of
between-study heterogeneity [25]. We evaluated pres-
ence of publication bias with funnel plots and statisti-
cally tested for funnel plot asymmetry using Egger’s test
[26].
Analyses were performed with R (version 2.15.1, R
Foundation for Statistical Computing, Vienna, Austria)
[27] with the package ‘lme4’ [28] and ‘meta’ [29]. All
statistical tests were two-sided and a p-value of 0.05 or
less was considered statistically significant. Prevalence
estimates are reported with corresponding 95% logit
confidence intervals (CI).
Results
The search yielded 1,629 articles in MEDLINE and
270 articles in EMBASE. After removal of 194 dupli-
cates, 1,705 unique articles were left for evaluation. Of
these, we excluded 1,476 articles based on title and
abstract, and 104 articles based on full text screening
(Figure 1). Reference cross-checking of the selected
articles yielded two additional studies that were
initially missed, as synonyms for breast were not
included in the title or abstract [30,31]. Of the 127
selected articles (CAIX [9,32-71], GLUT1 [30,31,33,34,
36,39,42,45,46,49,53,62,65,67,69,72-91], CXCR4 [92-121]
IGF1R [36,122-156]), we excluded ten articles from the
analysis due to (suspected) overlap of study populations
[38,43,61,62,94,109,123,139,143,153], and one article [67]
because we could not distinguish between carcinoma
in situ and invasive breast cancer. Ten articles [33,34,39,
42,45,46,49,53,65,69] described both GLUT1 and CAIX
expression, and one study [36] described IGF1R, CAIX,
and GLUT1 expression. In three of these studies,
co-expression patterns of CAIX and GLUT1 were
Table 2 Systematic review, meta-analysis and meta-regression results of hypoxia membrane protein expression in breast cancer, in situ carcinoma, benign
breast disease, and normal breast tissue.
CAIX GLUT1 CXCR4 IGF1R
N Prev. (CI) p-value* N Prev. (CI) p-value* N Prev. (CI) p-value* N Prev. (CI) p-value*
Invasive carcinoma
Overall 36 0.35 (0.26-0.46) Ref 33 0.51 (0.40-0.61) Ref 28 0.46 (0.33-0.59) Ref 31 0.46 (0.35-0.70) Ref
Membranous localization only 20 0.23 (0.17-0.31) - 19 0.44 (0.37-0.52) - 2 0.16 (0.08-0.31) - 15 0.38 (0.27-0.50) -
Best evidence studies 6 0.38 (0.17-0.65) - 17 0.41 (0.35-0.48) - 7 0.43 (0.25-0.63) - 10 0.33 (0.22-0.46) -
Histological grade 12 10 13 5
I 0.04 (0.02-0.08) Ref 0.24 (0.18-0.31) Ref 0.26 (0.13-0.44) Ref 0.57 (0.51-0.63) Ref
II 0.16 (0.10-0.24) <0.001 0.33 (0.20-0.50) 0.012 0.32 (0.17-0.52) 0.049 0.51 (0.49-0.54) 0.093
III 0.30 (0.22-0.39) <0.001 0.58 (0.45-0.69) <0.001 0.44 (0.26-0.63) <0.001 0.41 (0.39-0.43) <0.001
Tumor size 7 6 12 4
T1 0.12 (0.11-0.14) Ref 0.37 (0.31-0.42) Ref 0.48 (0.28-0.69) Ref 0.45 (0.39-0.51) Ref
T2 0.15 (0.11-0.20) <0.001 0.36 (0.29-0.43) 0.641 0.52 (0.28-0.74) 0.620 0.47 (0.44-0.49) 0.682
T3 0.30 (0.17-0.47) <0.001 0.30 (0.14-0.53) 0.180 0.68 (0.53-0.80) 0.122 0.39 (0.32-0.47) 0.047
Histological type 13 14 10 6
Invasive ductal carcinoma 0.34 (0.20-0.52) Ref 0.48 (0.32-0.64) Ref 0.46 (0.22-0.72) Ref 0.42 (0.28-0.58) Ref
Invasive lobular carcinoma 0.01 (0.00-0.05) 0.001 0.09 (0.01-0.40) <0.001 0.35 (0.00-0.98) 0.001 0.25 (0.08-0.55) <0.001
Specimen handling 36 32 28 31
Full sections 0.51 (0.37-0.64) Ref 0.61 (0.49-0.72) Ref 0.39 (0.28-0.51) Ref 0.34 (0.26-0.42) Ref
Tissue microarray 0.24 (0.16-0.35) 0.002 0.30 (0.18-0.45) 0.003 0.61 (0.29-0.85) 0.173 0.57 (0.39-0.73) 0.032
Other tissue types 4 5 6 4
Normal breast tissue 0.02 (0.00-0.50) <0.001 0.03 (0.00-0.22) <0.001 0.03 (0.01-0.07) <0.001 0.74 (0.69-0.78) 0.109
Benign breast diseases 0.06 (0.02-0.20) <0.001 0.04 (0.00-0.42) <0.001 0.04 (0.00-0.80) <0.001 0.73 (0.66-0.79) 0.137
Carcinoma in situ 0.49 (0.31-0.68) 0.025 0.52 (0.42-0.62) 0.680 0.71 (0.23-0.95) <0.001 0.33 (0.18-0.53) 0.869
*p-values obtained using meta-regression (linear mixed model with subgroup indicators as fixed and the individual studies as random effects); ref: reference
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Figure 3 Expression prevalence of GLUT1. A Systematic literature review of GLUT1 prevalence in breast cancer assessed by immunohistochemistry,
according to reported staining threshold. Legend: Dashed gray reference line: overall random-effects prevalence estimate. Abbreviations: Staining
threshold: weak intensity (WI), moderate intensity (MI), strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not
stated (NS). B Systematic literature review of GLUT 1 prevalence in normal breast tissue, benign breast diseases and carcinoma in situ assessed by
immunohistochemistry. Legend: Dashed line represents random effect summary prevalence estimate for invasive cancer within studies reporting
also on normal, benign and/or precancerous breast tissue ( 5 studies). Abbreviations: Staining threshold: weak intensity (WI), moderate intensity
(MI), strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not stated (NS).
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vestigated studies are shown in Additional file 1: Table
S1A, Additional file 2: Table S1B, Additional file 3:
Table S1C, Additional file 4: Table S1D.
IHC methodology varied between the studies. For
assessment of CAIX expression, three different antibodies
were used, and in 11 studies (31%) only the manufacturer
was stated. In articles describing GLUT1 prevalence, six
different antibodies were used and in 23 studies (70%) only
the manufacturer was stated. For CXCR4, eight antibodies
were used and in seven studies (25%) the antibody data
was not reported, and for IGF1R, 11 different antibodies
were used, and five studies (16%) did not specify the clone
used. In addition, 51 studies (44%) investigated TMAs to
evaluate the expression of the target of interest. Only 32
studies (63%) using TMAs reported the number of cores,
and 37 studies (73%) reported the diameter of the cores. In
43 of the studies (37%) no information was available on
who assessed staining results, 18 studies (15%) reported
evaluation by a single observer and in 56 studies (48%) by
more than one observer. In 43 of the studies (37%), it was
explicitly stated that evaluation was performed by one or
more pathologists.
CAIX
A total of 36 articles including 10,885 invasive cancers
(range of 10 to 3,630 cancers per study) reported on
CAIX expression, with prevalence estimates ranging from
7% to 92%. The overall pooled prevalence of CAIX was
35% (CI 26-46%; Figure 2A and Table 2). For studies
investigating membranous staining patterns only, we
found a pooled expression prevalence of 23% (CI 17-31%,
20 studies; Additional file 5: Figure S1A) and the studies
providing best evidence for evaluation of molecular
imaging targets showed a pooled prevalence of 38%
(CI 17-65%, 6 studies; Additional file 6: Figure S1B).
Expression prevalence of CAIX increased with histo-
logical grade (16% in grade II (p < 0.001) and 30% in
grade III (p < 0.001) versus 4% in grade I; Additional file 7:
Figure S1C), and tumor size (15% in T2 (p < 0.001) and
30% in T3 (p < 0.001) versus 12% in T1; Additional file 8:
Figure S1D). Prevalence of CAIX was also higher in invasive
ductal carcinoma (IDC) compared to invasive lobular car-
cinoma (ILC) (34% versus 1%, p = 0.001; Additional file 9:
Figure S1E). CAIX expression was more often positivein studies investigating full sections compared to TMA
(51% versus 24%, p = 0.002; Additional file 10: Figure S1F).
In normal breast tissue, the pooled prevalence was 2%
(CI 0-50%, p < 0.001; 4 studies). Pooled prevalence in
benign lesions was 6% (CI 2-20%, p < 0.001; 3 studies),
and in carcinoma in situ 49% (CI 31-68%, p = 0.025; 4
studies) (Figure 2B). Overall, between study-heterogeneity
of studies investigating CAIX expression was large, but
this decreased when confining analyses to membranous-
only and best evidence studies (these study groups largely
overlapped). Between-study variation was also lower
within subgroups of tumor grade and tumor size.
GLUT1
A total of 33 articles including 3,633 invasive cancers
reported on GLUT1 expression, with a range of 11 to
458 cancers per study. The overall pooled prevalence of
GLUT1 expression was 51% (CI 40-61%; Figure 3A and
Table 2), but the reported prevalence varied substantially
between studies (range 5% to 100%). For studies investi-
gating membranous staining patterns only, the pooled
prevalence was 44% (CI 37-52%, 19 studies; Additional
file 11: Figure S2A) and when the studies providing best
evidence for evaluation of molecular imaging targets were
selected, this was 41% (CI 35-48%; 17 studies; Additional
file 12: Figure S2B). GLUT1 prevalence was higher for
grade III (58%, p < 0.001) and grade II tumors (33%, p =
0.012) compared to grade I tumors (24%; Additional file 13:
Figure S2C), but there was no relation with tumor size
(Additional file 14: Figure S2D). Furthermore, as for
CAIX, expression prevalence in ILC was lower compared
to IDC (9% versus 48%, p < 0.001; Additional file 15:
Figure S2E). Studies investigating TMAs reported lower
prevalence of GLUT1 expression compared to studies
using full sections (30% versus 61%, p = 0.003, Additional
file 16: Figure S2F). In normal breast tissue, the pooled
expression prevalence was 3% (CI 0-22%, p < 0.001; 5
studies). Pooled prevalence in benign lesions was 5% (CI
0-42%, p < 0.001; 3 studies), and in carcinoma in situ 52%
(CI 42-62%, p = 0.680; 3 studies) (Figure 3B). For GLUT1,
the overall between-study variation was large as well, but
substantially smaller for studies investigating membranous
staining only and the best evidence studies (these study
groups again largely overlapped). Furthermore, the
Figure 4 (See legend on next page.)
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Figure 4 Expression prevalence of CXCR4. A Systematic literature review of CXCR4 prevalence in breast cancer assessed by immunohistochemistry,
according to reported staining threshold. Legend: Dashed gray reference line: overall random-effects prevalence estimate. Abbreviations: Staining
threshold: weak intensity (WI), moderate intensity (MI), strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not
stated (NS). B Systematic literature review of CXCR4 prevalence in normal breast tissue, benign breast diseases and carcinoma in situ assessed by
immunohistochemistry. Legend: Dashed line represents random effect summary prevalence estimate for invasive cancer within studies reporting
also on normal, benign and/or precancerous breast tissue (6 studies). Abbreviations: Staining threshold: weak intensity (WI), moderate intensity (MI),
strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not stated (NS).
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tumor size into account, and somewhat lower within
subgroups of grade. In the studies investigating co-
expression patterns of GLUT1 and CAIX, concordant
presence or absence of CAIX and GLUT1 was found in
78/118 (66%) [42], 45/59 (76%) [45], and 45/48 (94%) [69]
of the cancers, respectively.
CXCR4
A total of 28 articles including 5,583 invasive cancers re-
ported on CXCR4 expression, with a range of 7 to 1,808
cancers per study. The pooled prevalence of CXCR4
expression was 46% (CI 33-59%; Figure 4A and Table 2),
with a range between studies of 8% to 100%. For stu-
dies investigating membranous staining patterns only,
the pooled prevalence was 16% (CI 8-31%; 2 studies;
Additional file 17: Figure S3A) and when the studies
providing best evidence for evaluation of molecular im-
aging targets were selected, this was 43% (CI 25-63%;
7 studies, Additional file 18: Figure S3B). CXCR4 preva-
lence increased with histological grade (32% in grade II
(p = 0.049) and 44% in grade III (p < 0.001), compared
to 26% in grade I; Additional file 19: Figure S3C), but no
relation was found with tumor size (Additional file 20:
Figure S3D). Furthermore, the prevalence of CXCR4
was higher in IDC than in ILC (46% versus 35%, p =
0.001; Additional file 21: Figure S3E). Expression preva-
lence was not related to slide construction method
(Additional file 22: Figure S3F). In normal breast tissue,
the pooled expression prevalence was 3% (CI 1-7%, p <
0.001; 4 studies). Pooled prevalence in benign lesions was
4% (CI 0-80%, p < 0.001; 4 studies), and in carcinoma
in situ 71% (CI 23-95%, p < 0.001; 2 studies) (Figure 4B).
Between-study heterogeneity of studies investigating
CXCR4 expression was large, both overall and within all
subgroups (except for the two studies investigating
membranous staining).
IGF1R
We analyzed a total of 31 articles including 8,463 invasive
cancers (range of 8 to 2,871 cancers per study). The pooled
prevalence of IGF1R expression was 46% (CI 35-57%;
Figure 5A and Table 2) with a range between studies
of 10% to 99%. For studies investigating membranousstaining patterns only, the pooled prevalence was 38%
(CI 27-50%; 15 studies, Additional file 23: Figure S4A) and
when the studies providing best evidence for evaluation of
molecular imaging targets were selected, this was 33%
(CI 22-46%; 10 studies, Additional file 24: Figure S4B). In
contrast to the other investigated markers, the pooled
prevalence of IGF1R was lower in grade III versus grade I
cancers (41% versus 57%, p < 0.001; Additional file 25:
Figure S4C), and was lower in T3 cancers compared to T1
cancers (39% versus 45%, p = 0.047; Additional file 26:
Figure S4D). Prevalence of IGF1R was higher in IDC com-
pared to ILC (42% versus 25%, p < 0.001; Additional file 27:
Figure S4E), and higher in studies using TMAs than in
studies using full sections (57% versus 34%, p = 0.032;
Additional file 28: Figure S4F). In normal breast tissue, the
pooled expression prevalence was 74% (CI 69-78%, p =
0.109; 2 studies). Pooled prevalence in benign lesions was
73% (CI 66-79%, p = 0.137; 2 studies), and in carcinoma
in situ 33% (CI 18-53%, p = 0.869; 2 studies) (Figure 5B).
Variation in results between studies was large, both overall
and within the studies investigating membranous staining
only and best evidence studies. Within groups of tumor
grade and size, the between-study heterogeneity was very
low, but the number of studies in these subgroups was
small.
Evaluation of publication bias
The substantial overall between-study heterogeneity in
prevalence estimates was confirmed by examination of the
funnel plots (not shown). Furthermore, smaller studies
(i.e. with lower precision) were more likely to report
higher hypoxia marker prevalence rates (all Egger’s tests
p < 0.05, except for IGF1R). Funnel plots evaluating hypoxia
marker prevalence rates according to tumor grade showed
no evidence for publication bias for GLUT1 and CXCR4
(all Egger’s tests p > 0.25), but indicated that smaller stu-
dies showed a larger increase in CAIX prevalence for grade
III versus I and a larger decrease in IGF1R prevalence for
grade II versus grade I tumors (i.e. more extreme effects in
small studies; Egger’s tests p = 0.044 and p = 0.023, respec-
tively). We found no indication for publication bias when
evaluating the studies reporting on hypoxia marker
prevalence rates according to tumor size (all Egger’s tests
p > 0.15, or too few studies for evaluation).
Figure 5 (See legend on next page.)
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Figure 5 Expression prevalence of IGF1R. A Systematic literature review of IGF1R prevalence in breast cancer assessed by immunohistochemistry,
according to reported staining threshold. Legend: Dashed gray reference line: overall random-effects prevalence estimate. Abbreviations: Staining
threshold: weak intensity (WI), moderate intensity (MI), strong intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not
stated (NS). B Systematic literature review of IGF1R prevalence in normal breast tissue, benign breast diseases and carcinoma in situ assessed by
immunohistochemistry. Legend: Dashed line represents random effect summary prevalence estimate for invasive cancer within studies reporting also
on normal, benign and/or precancerous breast tissue ( 4 studies). Abbreviations: Staining threshold: weak intensity (WI), moderate intensity (MI), strong
intensity (SI); Localization: cytoplasm (c), membrane (m); confidence interval (CI); not stated (NS).
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In this comprehensive systematic literature review and
meta-analysis, we reported on expression prevalence of the
hypoxia-related proteins GLUT1, CAIX, CXCR4, and
IGF1R in breast cancer and carcinoma in situ, benign
breast disease and normal breast tissue. We included a total
of 117 articles totaling 30,216 IHC results. Hypoxia marker
prevalence rates were in the range of other potential
targets for molecular imaging with antibodies or antibody
fragments, e.g. Epidermal Growth Factor Receptor (EGFR)
[157] or CD44v6 [158], and were higher than for example
Human Epidermal Growth Factor Receptor 2 (HER2)
[159]. Benign breast disease and non-affected breast tissue
showed low expression, but the number of available studies
was limited. The between-study variation of results was
substantial and meta-regression showed several clinicopatho-
logical features of breast cancer to significantly influence
hypoxia marker expression.
CAIX, GLUT1, and CXCR4 prevalence rates significantly
increased with histological grade, which is consistent with
the hypothesis that high grade tumors have a higher prolife-
ration rate, causing neo-angiogenesis to lag behind tumor
growth [160]. The resulting inadequate nutrient and oxygen
supply causes activation of the hypoxia pathway [161,162].
Surprisingly, we found an inverse relation for IGF1R with
histological grade. In analogy to histological grade, larger
tumors may also express hypoxia markers more frequently,
but we only found a significant positive relation for CAIX,
and again an unexpected negative significant relation with
IGF1R. We further found that hypoxia proteins are infre-
quently expressed in ILC, suggesting that hypoxia is not a
common phenomenon in these cancers. Ercan et al.
reported that only 3% of ILC expresses HIF1α, compared
to 39% of IDC [163], suggesting that hypoxia is indeed rare
in this subtype. We found significant lower expression
prevalences in normal tissue and benign breast diseases
compared to invasive breast cancer, showing high cancer-
specificity of CAIX, GLUT1 and especially CXCR4. IGF1R
was evaluated in few studies with non-significant results, so
no conclusions can be drawn with respect to specificity of
this target. Pooled expression prevalence rates of carcinoma
in situ were at least comparable to (GLUT1 and IGF1R) or
higher than (CAIX and CXCR4) invasive carcinoma, albeit
based on few studies.An increasing number of recent studies evaluated
hypoxia marker expression using TMA. Although TMA
allows for higher throughput than full section analyses, it
may lead to underestimation of marker expression in
presence of intra-tumoral heterogeneity. We found that
CAIX and GLUT1 prevalence was significantly lower in
TMA studies, presumably due to the sampling method
used for TMA construction, in which necrotic regions
that usually have the highest expression of hypoxia-
related proteins are avoided [65]. The lower prevalence
of CAIX and GLUT1 in TMA studies could be inter-
preted as an indication of intratumoral heterogeneity of
these markers. Although this interpretation is interesting,
the applicability of TMAs for assessment of hypoxia
marker expression needs to be reconsidered [164,165],
even if their use has been justified for other markers (e.g.
ERα and HER2 [143,166]).
With a view to molecular imaging, specificity of the
imaging target is pivotal for every clinical application.
The marked lower expression prevalence of CAIX,
GLUT1 and CXCR4 in benign breast disease and normal
breast tissue is thus highly promising. The specificity
results for IGF1R are less encouraging, albeit based on
only two studies. For early detection, a suitable target
should be prevalent already in small tumors. Furthermore,
evidence is mounting that current mammography screen-
ing may lead to substantial over-diagnosis [167] and
picks-up tumors with favorable prognosis [168]. An
imaging target that identifies small tumors with poor
prognosis, e.g. grade III invasive breast cancers [169],
would thus be especially valuable for screening. This
combination makes GLUT1 an interesting candidate, with
high expression in grade III cancers (58%) and also highest
expression in T1 tumors (although the latter not signifi-
cantly different from T3 tumors). CXCR4 and CAIX also
show higher expression in grade III cancers, but for CAIX
expression prevalence is markedly lower in smaller lesions.
For intra-operative guidance, a high prevalence in invasive
cancer is not required, as tissue can be sampled for inves-
tigation of target expression pre-operatively. Such a
target should ideally show low intratumoral heterogeneity
to ascertain radical resection. Although this was not
specifically addressed by individual studies, the difference
in results between TMA and full-section studies may
Adams et al. BMC Cancer 2013, 13:538 Page 13 of 19
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heterogeneity and might therefore be less suitable for
intra-operative application than CXCR4. Risk factors for
incomplete tumor resection in current clinical practice
include the presence of an extensive intraductal compo-
nent [170], and the ILC histological subtype [171-175].
Especially CXCR4 shows high expression in DCIS, thus is
potentially valuable for imaging of an extensive intraductal
component. However, none of the markers show potential
for ILC imaging.
None of the investigated markers showed a sufficient
expression prevalence to allow sensitive molecular imaging
with a single tracer only. For successful implementation
(especially in a screening or diagnostic setting), a com-
bination of tracers would be required to obtain a high
sensitivity. However, all of the investigated markers here
are expressed via the same (hypoxia-related) oncogenic
pathway. The few studies that investigated co-expression
patterns found that expression of these markers were
indeed closely correlated. It would therefore be more
advantageous to combine the hypoxia targets with targets
from other oncogenic pathways, such as growth factors
(e.g. EGFR or HER2), targets that are excreted in the
tumor stroma (e.g. Vascular Endothelial Growth Factor
(VEGF)), or less tumor-specific targets such as Mucin 1
(MUC1), Mammaglobin, or CD44v6 [36]. However, the
aggregated nature of the obtained data did not allow us
to investigate the best combination of targets or to
investigate co-expression patterns.
To appreciate the results, one needs to acknowledge
that studies employed various IHC protocols and assess-
ment methodologies, as no standardized scoring system is
established for these markers, in contrast to e.g. HER2
[176]. When we evaluated only studies that used relatively
strict cut-offs (i.e. the studies providing best evidence for
evaluation of molecular imaging targets) or studies investi-
gating membranous staining only, the results were still
comparable to the overall results. Nevertheless, as IHC
may not reflect the functionality or availability of a marker
in all situations, it remains unclear which or if any cut-off
level relates to sufficient marker levels for molecular im-
aging in humans [177]. However, IHC remains the estab-
lished standard for protein expression estimation since it
allows for sensitive detection at the (sub-) cellular level,
and is more reliable than assays measuring DNA or RNA
levels because of post-translational processing.
Conclusions
We have shown that human expression prevalence and
patterns of hypoxia-related markers support their potential
as molecular imaging targets, with promising specificity.
However, none of the evaluated markers shows sufficient
prevalence in invasive cancer to be exploited as the sole tar-
get. Future research should focus on the identification ofoptimal combinations of candidate imaging targets, and
dedicated studies are needed to assess the accuracy of such
combinations to discriminate between breast cancer (sub-
types) and benign breast lesions and normal tissue. The
data from this review and such studies could help guide the
choice of markers for breast cancer tracer development.Additional files
Additional file 1: Table S1A. Study characteristics of articles included
in the review investigating CAIX expression prevalences in breast cancer,
carcinoma in situ, benign breast disease, and normal breast tissue
Legend: a: mean; *: mean size in mm (range or SD); b: nuclear grade; ns:
not stated; na: not applicable; ○: tissue not investigated; ●: tissue
investigated; ◉: both TMA and full sections investigated; IDC: invasive
ductal carcinoma; ILC: invasive lobular carcinoma; IBC: inflammatory
breast cancer; ABC: advanced breast cancer; TN: triple negative; LN:
lymph node; TMA: tissue microarray; PT: phyllodes tumors; FA:
fibroadenoma; M: distant metastasis; Obs.: number of observers
evaluating staining result; +: positive; -: negative.
Additional file 2: Table S1B. Study characteristics of articles included
in the review investigating GLUT1 expression prevalences in breast
cancer, carcinoma in situ, benign breast disease, and normal breast tissue.
Legend: a: mean; *: mean size in mm (range or SD); b: nuclear grade; ns:
not stated; na: not applicable; ○: tissue not investigated; ●: tissue
investigated; ◉: both TMA and full sections investigated; IDC: invasive
ductal carcinoma; ILC: invasive lobular carcinoma; IBC: inflammatory
breast cancer; ABC: advanced breast cancer; TN: triple negative; LN:
lymph node; TMA: tissue microarray; PT: phyllodes tumors; FA:
fibroadenoma; M: distant metastasis; Obs.: number of observers
evaluating staining result; +: positive; -: negative.
Additional file 3: Table S1C. Study characteristics of articles included
in the review investigating CXCR4 expression prevalences in breast
cancer, in situ carcinoma, benign breast disease, and normal breast
tissue. Legend: a: mean; *: mean size in mm (range or SD); b: nuclear
grade; ns: not stated; na: not applicable; ○: tissue not investigated; ●:
tissue investigated; ◉: both TMA and full sections investigated; IDC:
invasive ductal carcinoma; ILC: invasive lobular carcinoma; IBC:
inflammatory breast cancer; ABC: advanced breast cancer; TN: triple
negative; LN: lymph node; TMA: tissue microarray; PT: phyllodes tumors;
FA: fibroadenoma; M: distant metastasis; Obs.: number of observers
evaluating staining result; +: positive; -: negative.
Additional file 4: Table S1D. Study characteristics of articles included
in the review investigating IGF1R expression prevalences in breast cancer,
carcinoma in situ, benign breast disease, and normal breast tissue.
Legend: a: mean; *: mean size in mm (range or SD); b: nuclear grade; ns:
not stated; na: not applicable; ○: tissue not investigated; ●: tissue investigated;
◉: both TMA and full sections investigated; IDC: invasive ductal carcinoma;
ILC: invasive lobular carcinoma; IBC: inflammatory breast cancer; ABC:
advanced breast cancer; TN: triple negative; LN: lymph node; TMA: tissue
microarray; PT: phyllodes tumors; FA: fibroadenoma; M: distant metastasis;
Obs.: number of observers evaluating staining result; +: positive; -: negative.
Additional file 5: Figure S1A. CAIX - Membranous staining. Systematic
literature review of CAIX prevalence in breast cancer assessed by immunohis-
tochemistry for studies investigating membranous staining patterns only.
Additional file 6: Figure S1B. CAIX - Best evidence studies. Systematic
literature review of CAIX prevalence in breast cancer assessed by
immunohistochemistry for studies providing the best evidence for high
expression levels.
Additional file 7: Figure S1C. CAIX - Histological grade. Systematic
literature review of CAIX prevalence in breast cancer assessed by
immunohistochemistry in relation to histological grade.
Additional file 8: Figure S1D. CAIX - Tumor size. Systematic literature
review of CAIX prevalence in breast cancer assessed by
immunohistochemistry in relation to tumor size.
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http://www.biomedcentral.com/1471-2407/13/538Additional file 9: Figure S1E. CAIX - Histology. Systematic literature
review of CAIX prevalence in breast cancer assessed by
immunohistochemistry in relation to histological subtype.
Additional file 10: Figure S1F. CAIX - Specimen handling.
Systematic literature review of CAIX prevalence in breast cancer assessed by
immunohistochemistry in relation to specimen handling method.
Additional file 11: Figure S2A. GLUT1 - Membranous staining.
Systematic literature review of GLUT1 prevalence in breast cancer
assessed by immunohistochemistry for studies investigating membranous
staining patterns only.
Additional file 12: Figure S2B. GLUT1 - Best evidence studies.
Systematic literature review of GLUT1 prevalence in breast cancer
assessed by immunohistochemistry for studies providing the best
evidence for high expression levels.
Additional file 13: Figure S2C. GLUT1 - Histological grade. Systematic
literature review of GLUT1 prevalence in breast cancer assessed by
immunohistochemistry in relation to histological grade.
Additional file 14: Figure S2D. GLUT1 - Tumor size. Systematic
literature review of GLUT1 prevalence in breast cancer assessed by
immunohistochemistry in relation to tumor size.
Additional file 15: Figure S2E. GLUT1 - Histology. Systematic literature
review of GLUT1 prevalence in breast cancer assessed by
immunohistochemistry in relation to histological subtype.
Additional file 16: Figure S2F. GLUT1 - Specimen handling. Systematic
literature review of GLUT1 prevalence in breast cancer assessed by
immunohistochemistry in relation to specimen handling method.
Additional file 17: Figure S3A. CXCR4 - Membranous staining.
Systematic literature review of CXCR4 prevalence in breast cancer
assessed by immunohistochemistry for studies investigating membranous
staining patterns only.
Additional file 18: Figure S3B. CXCR4 - Best evidence studies.
Systematic literature review of CXCR4 prevalence in breast cancer
assessed by immunohistochemistry for studies providing the best
evidence for high expression levels.
Additional file 19: Figure S3C. CXCR4 - Histological grade. Systematic
literature review of CXCR4 prevalence in breast cancer assessed by
immunohistochemistry in relation to histological grade.
Additional file 20: Figure S3D. CXCR4 - Tumor size. Systematic
literature review of CXCR4 prevalence in breast cancer assessed by
immunohistochemistry in relation to tumor size.
Additional file 21: Figure S3E. CXCR4 - Histology. Systematic literature
review of CXCR4 prevalence in breast cancer assessed by
immunohistochemistry in relation to histological subtype.
Additional file 22: Figure S3F. CXCR4 - Specimen handling. Systematic
literature review of CXCR4 prevalence in breast cancer assessed by
immunohistochemistry in relation to specimen handling method.
Additional file 23: Figure S4A. IGF1R - Membranous staining.
Systematic literature review of IGF1R prevalence in breast cancer assessed
by immunohistochemistry for studies investigating membranous staining
patterns only.
Additional file 24: Figure S4B. IGF1R - Best evidence studies.
Systematic literature review of IGF1R prevalence in breast cancer assessed
by immunohistochemistry for studies providing the best evidence for
high expression levels.
Additional file 25: Figure S4C. IGF1R - Histological grade. Systematic
literature review of IGF1R prevalence in breast cancer assessed by
immunohistochemistry in relation to histological grade.
Additional file 26: Figure S4D. IGF1R - Tumor size. Systematic
literature review of IGF1R prevalence in breast cancer assessed by
immunohistochemistry in relation to tumor size.
Additional file 27: Figure S4E. IGF1R - Histology. Systematic literature
review of IGF1R prevalence in breast cancer assessed by
immunohistochemistry in relation to histological subtype.Additional file 28: Figure S4F. IGF1R - Specimen handling. Systematic
literature review of IGF1R prevalence in breast cancer assessed by
immunohistochemistry in relation to specimen handling method.
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